COMPASS Pathways, a healthcare company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it is partnering with Worldwide Clinical Trials to conduct a major program of late-stage clinical trials for psilocybin therapy for treatment-resistant depression. Depression is the leading cause of ill-health and disability worldwide, and one of the fastest growing health […]
The post First large-scale clinical trials in psilocybin therapy for treatment-resistant depression launches appeared first on CenterWatch News Online.
Powered by WPeMatico